3
Announcements
Trials
Browse
Landscape
Status
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
32
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
3
Lymphoid
3
Plasma cell
1
Myeloid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Amyloidosis
1
Interventions
elotuzumab
4
Bortezomib
4
Lenalidomide
3
Dexamethasone
3
talquetamab
2
selinexor
2
pomalidomide
2
carfilzomib
2
Panobinostat
2
venetoclax
1
ulocuplumab
1
plerixafor
1
idecabtagene vicleucel
1
fludarabine phosphate
1
daratumumab
1
ceritinib
1
belantamab mafodotin
1
Whole-Body Irradiation
1
Tacrolimus
1
Prednisone
1
Mycophenolic Acid
1
Melphalan
1
Cytarabine
1
Crizotinib
1
Cord Blood Stem Cell Transplantation
1
Calcium Dobesilate
1
Busulfan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Expanded_access
×
venetoclax
×
Plasma cell
×
Clear all
NCT03123029
2026-01-30
Expanded Access to Venetoclax
AbbVie
Available